Cargando…

JMJD5 is a human arginyl C-3 hydroxylase

Oxygenase-catalysed post-translational modifications of basic protein residues, including lysyl hydroxylations and N(ε)-methyl lysyl demethylations, have important cellular roles. Jumonji-C (JmjC) domain-containing protein 5 (JMJD5), which genetic studies reveal is essential in animal development, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkins, Sarah E., Islam, Md. Saiful, Gannon, Joan M., Markolovic, Suzana, Hopkinson, Richard J., Ge, Wei, Schofield, Christopher J., Chowdhury, Rasheduzzaman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862942/
https://www.ncbi.nlm.nih.gov/pubmed/29563586
http://dx.doi.org/10.1038/s41467-018-03410-w
Descripción
Sumario:Oxygenase-catalysed post-translational modifications of basic protein residues, including lysyl hydroxylations and N(ε)-methyl lysyl demethylations, have important cellular roles. Jumonji-C (JmjC) domain-containing protein 5 (JMJD5), which genetic studies reveal is essential in animal development, is reported as a histone N(ε)-methyl lysine demethylase (KDM). Here we report how extensive screening with peptides based on JMJD5 interacting proteins led to the finding that JMJD5 catalyses stereoselective C-3 hydroxylation of arginine residues in sequences from human regulator of chromosome condensation domain-containing protein 1 (RCCD1) and ribosomal protein S6 (RPS6). High-resolution crystallographic analyses reveal overall fold, active site and substrate binding/product release features supporting the assignment of JMJD5 as an arginine hydroxylase rather than a KDM. The results will be useful in the development of selective oxygenase inhibitors for the treatment of cancer and genetic diseases.